Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. - Kudo M; Ren Z; Guo Y; Han G; Lin H; Zheng J; Ogasawara S; Kim JH; Zhao H; Li C; Madoff DC; Ghobrial RM; et al. (Lancet (London, England), 2025)